[Chinese expert consensus on antithrombotic therapy of panvascular diseases (2024 edition)].

Abstract

Panvascular disease is a systemic condition with vascular lesions (95% of which are atherosclerosis) as the common pathological feature, which can be manifested as coronary artery disease, cerebrovascular disease, peripheral artery disease, etc., or a combination of two or more vascular bed diseases that is called multivascular disease. The burden of panvascular diseases in China is heavy, and improvement of patient prognosis is urgently needed. Although the management of panvascular diseases belongs to different disciplines, they often share common risk factors and pathophysiological mechanisms that warrant standardized treatment strategies. Antithrombotic therapy for panvascular diseases mainly includes antiplatelet and anticoagulant therapy. For patients with different ischemic and bleeding risks and different stages of the disease, there is currently a lack of unified guidance from various disciplines. Given the crucial role of standardized antithrombotic therapy in the treatment of panvascular disease, Chinese College of Cardiovascular Physicians led the organization of a consensus working group consisting of 33 senior experts in the fields of cardiology, vascular surgery, neurology, and endocrinology. "Chinese expert consensus on antithrombotic therapy of panvascular diseases (2024 edition)" was developed based on specific treatment needs of panvascular diseases in China, combined with published clinical research evidence, specialized guidelines and consensus, as well as the recommendations from the consensus expert group. The primary objective of this consensus is to standardize the application of antithrombotic therapy in panvascular diseases, thereby optimizing clinical outcomes, improving patients prognosis, and mitigating the economic and societal burden associated with panvascular disease.